Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy

Completed · Phase 2

Conditions studied: Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting

In brief

This study was designed to assess the safety and efficacy of different dosages and administration schedules of an investigational agent administered over 3 days when added to standard therapy used in the prevention of chemotherapy-induced nausea and vomiting in cancer patients. Subjects will be asked to complete daily diaries while on study medication. In addition subjects will be required to return to the investigational site several times during the course of the study for follow up safety assessments which may include blood samples for hematology and chemistry evaluations as well as physical exams. A final assessment will be preformed on study Day 20-30 at which time the subject will complete the study.

Key facts

Study ID

NCT00104403

Run by

GlaxoSmithKline

People needed

722

Starts

2004-12-01

Expected to finish

2006-01-01

Last updated by the study team

2015-04-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Willing to provide a written informed consent prior to receiving any study-specific procedures or assessments.
• Diagnosed with a solid malignant tumor and has not previously received chemotherapy.
• Scheduled to receive chemotherapy conducive to regimens outlined in the study protocol.

You may not qualify if…

• Not received any investigational product within 30 days of enrollment into the study.
• Must not be pregnant.
• Must not be of childbearing potential or is willing to use specific barrier methods outlined in the protocol.
• Must not be scheduled to receive radiation therapy to the abdomen or to the pelvis within seven (7) days prior to starting study medication.
• Must not be currently under treatment for a condition which may cause nausea or vomiting (i.e., active peptic ulcer disease, gastric obstruction).
• Must not have a history of peptic ulcer disease.

Where it is running

• GSK Investigational Site — Corona, California, United States
• GSK Investigational Site — Greenbrae, California, United States
• GSK Investigational Site — Loma Linda, California, United States
• GSK Investigational Site — Los Angeles, California, United States
• GSK Investigational Site — Palm Springs, California, United States
• GSK Investigational Site — Lakewood, Colorado, United States
• GSK Investigational Site — Boynton Beach, Florida, United States
• GSK Investigational Site — Hudson, Florida, United States
• GSK Investigational Site — Miami, Florida, United States
• GSK Investigational Site — Ocala, Florida, United States
• GSK Investigational Site — Centralia, Illinois, United States
• GSK Investigational Site — Park Ridge, Illinois, United States
• GSK Investigational Site — Skokie, Illinois, United States
• GSK Investigational Site — Evansville, Indiana, United States
• GSK Investigational Site — Muncie, Indiana, United States
• GSK Investigational Site — New Albany, Indiana, United States
• GSK Investigational Site — Hutchinson, Kansas, United States
• GSK Investigational Site — Alexandria, Louisiana, United States
• GSK Investigational Site — Baton Rouge, Louisiana, United States
• GSK Investigational Site — Bethesda, Maryland, United States
• GSK Investigational Site — Worcester, Massachusetts, United States
• GSK Investigational Site — Bay City, Michigan, United States
• GSK Investigational Site — Tupelo, Mississippi, United States
• GSK Investigational Site — Jefferson City, Missouri, United States
• GSK Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.